Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis

Trial Profile

A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs KPL-716 (Primary)
  • Indications Prurigo nodularis; Pruritus
  • Focus Therapeutic Use
  • Sponsors Kiniksa Pharmaceuticals
  • Most Recent Events

    • 05 Feb 2019 Planned initiation date changed from 1 Jun 2019 to 1 Mar 2019.
    • 23 Jan 2019 Status changed from planning to not yet recruiting.
    • 01 Nov 2018 According to a Kiniksa Pharmaceuticals media release, study eill start in Q1 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top